| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $22,023,904 | 7 | 15 |
Sells | $47,221,316 | 40 | 85 |
| HEALY JAMES | director | 1 | $20.36M | 0 | $0 | $20.36M |
| PAUL STEVEN M | director | 1 | $974,278 | 0 | $0 | $974,278 |
| MARAGANORE JOHN | director | 1 | $248,891 | 0 | $0 | $248,891 |
| Ignelzi Troy A. | Chief Financial Officer | 1 | $143,550 | 0 | $0 | $143,550 |
| Young Wendy B. | director | 1 | $99,992 | 0 | $0 | $99,992 |
| Silva Paul M | director | 1 | $99,636 | 0 | $0 | $99,636 |
| Sanchez Ramiro | director | 1 | $98,478 | 0 | $0 | $98,478 |
| Bredt David | Chief Scientific Officer | 0 | $0 | 5 | $1.14M | $-1.14M |
| Gault Cheryl | Chief Operating Officer | 0 | $0 | 5 | $1.24M | $-1.24M |
| Yeleswaram Krishnaswamy | Chief Development Officer | 0 | $0 | 10 | $4.46M | $-4.46M |
| Ceesay Abraham | Chief Executive Officer | 0 | $0 | 15 | $5.99M | $-5.99M |
| Third Rock Ventures V, L.P. | 10 percent owner | 0 | $0 | 5 | $34.39M | $-34.39M |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral …
Over the last 12 months, insiders at Rapport Therapeutics, Inc. Common Stock have bought $22.02M and sold $47.22M worth of Rapport Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Rapport Therapeutics, Inc. Common Stock have bought $11.9M and sold $25.36M worth of stock each year.
Highest buying activity among insiders over the last 12 months: HEALY JAMES (director) — $20.36M. PAUL STEVEN M (director) — $974,278. MARAGANORE JOHN (director) — $248,891.
The last purchase of 969,480 shares for transaction amount of $20.36M was made by HEALY JAMES (director) on 2026‑10‑28.
| 2026-10-28 | HEALY JAMES | director | 969,480 1.886% | $21.00 | $20.36M | +11.51% | ||
| 2026-10-23 | Sanchez Ramiro | director | 3,600 0.0079% | $27.35 | $98,478 | -3.09% | ||
| 2026-10-22 | PAUL STEVEN M | director | 35,714 0.0765% | $27.28 | $974,278 | -4.90% | ||
| 2026-10-22 | Young Wendy B. | director | 3,789 0.0079% | $26.39 | $99,992 | -4.90% | ||
| 2026-10-22 | MARAGANORE JOHN | director | 9,411 0.0196% | $26.45 | $248,891 | -4.90% | ||
| 2026-10-22 | Silva Paul M | director | 3,680 0.0078% | $27.07 | $99,636 | -4.90% | ||
| 2026-10-21 | Sale | Ceesay Abraham | Chief Executive Officer | 2,210 0.0054% | $29.16 | $64,448 | +1.08% | |
| 2026-10-21 | Ignelzi Troy A. | Chief Financial Officer | 5,500 0.0119% | $26.10 | $143,550 | +1.08% | ||
| 2026-10-07 | Sale | Ceesay Abraham | Chief Executive Officer | 1,147 0.0024% | $30.66 | $35,167 | -10.76% | |
| 2026-10-06 | Sale | Ceesay Abraham | Chief Executive Officer | 3,375 0.0073% | $32.03 | $108,106 | -11.54% | |
| 2026-09-30 | Sale | Gault Cheryl | Chief Operating Officer | 10,000 0.0207% | $33.19 | $331,856 | -15.28% | |
| 2026-09-23 | Sale | Ceesay Abraham | Chief Executive Officer | 2,210 0.0053% | $39.17 | $86,565 | -13.95% | |
| 2026-09-08 | Sale | Ceesay Abraham | Chief Executive Officer | 8,210 0.0171% | $45.61 | $374,498 | -32.73% | |
| 2026-08-25 | Sale | Ceesay Abraham | Chief Executive Officer | 18,921 0.0383% | $49.57 | $937,957 | -35.47% | |
| 2026-08-25 | Sale | Yeleswaram Krishnaswamy | Chief Development Officer | 37,000 0.0766% | $50.64 | $1.87M | -35.47% | |
| 2026-08-24 | Sale | Yeleswaram Krishnaswamy | Chief Development Officer | 13,160 0.0281% | $50.00 | $657,978 | -32.64% | |
| 2026-08-19 | Sale | Yeleswaram Krishnaswamy | Chief Development Officer | 404 0.0009% | $49.90 | $20,160 | -31.53% | |
| 2026-08-11 | Sale | Ceesay Abraham | Chief Executive Officer | 28,958 0.0595% | $48.01 | $1.39M | -30.09% | |
| 2026-08-10 | Sale | Ceesay Abraham | Chief Executive Officer | 22,541 0.0468% | $46.26 | $1.04M | -21.47% | |
| 2026-07-27 | Sale | Ceesay Abraham | Chief Executive Officer | 2,210 0.0046% | $42.11 | $93,061 | -2.24% |
| HEALY JAMES | director | 2815707 5.8687% | $71.63M | 1 | 0 | |
| PAUL STEVEN M | director | 77380 0.1613% | $1.97M | 2 | 0 | +27.29% |
| Ignelzi Troy A. | Chief Financial Officer | 15500 0.0323% | $394,320.00 | 3 | 0 | |
| Young Wendy B. | director | 13289 0.0277% | $338,072.16 | 3 | 0 | +30.34% |
| MARAGANORE JOHN | director | 9411 0.0196% | $239,415.84 | 1 | 0 | |
| Silva Paul M | director | 3680 0.0077% | $93,619.20 | 1 | 0 | |
| Sanchez Ramiro | director | 3600 0.0075% | $91,584.00 | 1 | 0 | |
| Huber Reid M | director | 20400 0.0425% | $518,976.00 | 1 | 0 | +27.29% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$4,431,947 | 22 | 36.10% | $1.46B |
| Increased Positions | 91 | +75.83% | 5M | +10.08% |
| Decreased Positions | 49 | -40.83% | 3M | -6.42% |
| New Positions | 40 | New | 1M | New |
| Sold Out Positions | 20 | Sold Out | 951,104 | Sold Out |
| Total Postitions | 162 | +35% | 51M | +3.66% |